The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

Pharmacovigilance 2.0 – Let Freedom Ring in Philadelphia!

Posted by Jim Davis on April 28, 2017

Next week, May 3rd and 4th, will mark a big moment for Advera Health. Our Chief Product Officer Bob Kyle and I will be attending the World Drug Safety Congress in Philadelphia. The moment will be big, not because we are exhibiting for the first time (we are), or because we are demonstrating significant advances in drug safety data (we are), or even because I’m a huge fan of the Philadelphia Eagles (I am) and Bob has always dreamed of imitating Rocky and running the 72 stone steps before the entrance of the Philadelphia Museum of Art (he hasn’t).

Read More

Topics: Pharmacovigilance, Pharmacovigilantes, Pharmacovigiance 2.0, World Drug Safety Congress

Efficacy vs. Effectiveness - The Role of Pharmacovigilance

Posted by Jim Davis on March 17, 2017

I'm pleased to introduce Jill Notte, Director of Global Marketing, APCER Life Sciences, who authored this week's post.

 

 

 

As a marketing communications professional in the pharmaceutical industry, I try to choose my words carefully in everything I write. The field of drug safety, where I have spent the past 15 years of my career, is particularly choosy about its terms. Words have precise definitions, and so we say, for example, that an event is “suspected” when we haven’t yet confirmed whether it is “unexpected” or “serious.”

Read More

Topics: Pharmacovigilance, Pharmacovigilantes, Pharmacovigiance 2.0

Increasing Pressure for Increased Pharmacovgilance Capabilities

Posted by Jim Davis on February 17, 2017

A few weeks ago, I published a post in this blog, Drug Safety Progressives - The Rise of the Pharmacovigilante. I was blown away by the positive response and resulting discussions. I even received a few requests for the t-shirt shown in the picture, but I’m sorry to say that our business model is based on software-as-a-service, not retail. But I digress… back to the Pharmacovigilantes…

Read More

Topics: Pharmacovigilance, Pharmacovigilantes, Pharmacovigiance 2.0

Subscribe to Email Updates